Login to Your Account

FDA Gives OK to Genzyme's Aubagio in Multiple Sclerosis

By Catherine Shaffer
Staff Writer

Friday, September 14, 2012
The FDA approved Aubagio (teriflunomide) by Genzyme, a Sanofi SA company, as a new oral therapy for patients with relapsing multiple sclerosis (MS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription